Ampersand submits to list on AMEX (American Stock Exchange):
This article was originally published in Clinica
Ampersand Medical has submitted an application to list its common stock on the American Stock Exchange (AMEX). Shareholders of the Chicago company, which has developed the InPath system for cervical cancer screening, has approved a one-for-three reverse stock split. At its annual meeting, the company's CEO Peter Gombrich said: "We have set an aggressive schedule to get our products to market, first in emerging markets that are virtually untapped for cervical cancer screening, followed closely by the US and other developed markets."